AERI - アエリ―・ファ―マシュ―ティカルズ (Aerie Pharmaceuticals Inc.)

AERIのニュース

   Aerie Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update  2020/05/06 20:01:00 Business Wire
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and potentially other diseases of the eye, today reported financial results for the first quarter ended March 31, 2020 and provided a general business update, including the impact of the COVID-19 pandemic on company op
   Aerie Pharmaceuticals to Present at the Bank of America Securities 2020 Healthcare Conference  2020/05/05 11:30:00 Business Wire
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the Bank of America Securities 2020 Healthcare Conference on
   Aerie Pharmaceuticals to Announce First Quarter 2020 Financial Results and Host Conference Call on Wednesday, May 6, 2020  2020/04/29 11:30:00 Business Wire
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye announced today that its first quarter 2020 financial results will be released after the market closes on Wednesday, May 6, 2020. Following the release, the Company will host a live confer
   Aerie Pharmaceuticals (AERI) Expected to Beat Earnings Estimates: Should You Buy?  2020/04/28 16:34:00 Zacks Investment Research
Aerie (AERI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Aerie (AERI) Suspends Guidance Due to Coronavirus Outbreak  2020/04/13 09:01:00 Zacks Investment Research
Aerie (AERI) suspends annual guidance as volumes get impacted due to the COVID-19 outbreak.
   Aerie Pharmaceuticals to Announce First Quarter 2020 Financial Results and Host Conference Call on Wednesday, May 6, 2020  2020/04/29 11:30:00 Business Wire
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye announced today that its first quarter 2020 financial results will be released after the market closes on Wednesday, May 6, 2020. Following the release, the Company will host a live confer
   Aerie Pharmaceuticals (AERI) Expected to Beat Earnings Estimates: Should You Buy?  2020/04/28 16:34:00 Zacks Investment Research
Aerie (AERI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Aerie (AERI) Suspends Guidance Due to Coronavirus Outbreak  2020/04/13 09:01:00 Zacks Investment Research
Aerie (AERI) suspends annual guidance as volumes get impacted due to the COVID-19 outbreak.
   Aerie Pharmaceuticals Provides 2020 Company and Guidance Update Associated with COVID-19  2020/04/09 20:01:00 Business Wire
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye today provided a business update associated with the impact of the global Coronavirus disease (COVID-19) pandemic on Company operations. While Aerie volumes increased in the first-quarter
   Aerie Pharmaceuticals to Present at the Needham Virtual Healthcare Conference  2020/04/07 11:30:00 Business Wire
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the Needham Virtual Healthcare Conference on Tuesday, April 1
   Aerie (AERI) Suspends Guidance Due to Coronavirus Outbreak  2020/04/13 09:01:00 Zacks Investment Research
Aerie (AERI) suspends annual guidance as volumes get impacted due to the COVID-19 outbreak.
   Aerie Pharmaceuticals Provides 2020 Company and Guidance Update Associated with COVID-19  2020/04/09 20:01:00 Business Wire
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye today provided a business update associated with the impact of the global Coronavirus disease (COVID-19) pandemic on Company operations. While Aerie volumes increased in the first-quarter
   Aerie Pharmaceuticals to Present at the Needham Virtual Healthcare Conference  2020/04/07 11:30:00 Business Wire
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the Needham Virtual Healthcare Conference on Tuesday, April 1
   Why Is Aerie (AERI) Down 40.5% Since Last Earnings Report?  2020/03/21 15:30:51 Zacks Investment Research
Aerie (AERI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection  2020/03/19 11:37:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) Biomerica, Inc. (NASDAQ: BMRA )( announced commencement of international shipment of rapid COVID-19 test) BioNTech SE – ADR (NASDAQ: BNTX ) Imara Inc (NASDAQ: IMRA ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 18) 89bio Inc (NASDAQ: ETNB ) AC Immune SA (NASDAQ: ACIU ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) ADMA Biologics Inc (NASDAQ: ADMA ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Agenus Inc (NASDAQ: AGEN ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Aikido Pharma Inc (NASDAQ: AIKI ) Akorn, Inc. (NASDAQ: AKRX ) Alkermes Plc (NASDAQ: ALKS ) Allogene Therapeutics Inc (NASDAQ: ALLO ) Alterity Therapeutics Ltd (NASDAQ: ATHE ) AMAG Pharmaceuticals, Inc.

calendar